EGFR and non-small cell lung carcinoma: Naquotinib (Figure 2) is a 3-aminopyrazine-based drug that inhibits NSCLC cell lines with varied EGFR status (EGFRL858R, EGFRdel19, EGFRL858R/T790M, and EGFRdel19/T790M mutations) with IC50 = 8–33 nM.